Elicio reports ELI-002 7P Phase 1a DFS not yet reached at 4.9mg; biomarker responders have no progression

Elicio Therapeutics, Inc.

Median DFS not reached in 14 patients; median follow-up 29.1 weeks.
At 4.9mg AMP-peptide (n=8), median DFS not reached vs 12.6 weeks for 1.4mg (n=6).
Patients with tumor biomarker reduction had zero progression events; non-responders had median DFS 11.0 weeks.
Above-median T cell responders had no progression events as of May 24, 2024 data cutoff.
Phase 2 interim analysis (135 patients) expected Q1 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.